Exelixis Inc
NASDAQ:EXEL
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
32.38
46.26
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one
EXEL
stock under the Base Case scenario is
47.98
USD.
Compared to the current market price of 41.28 USD,
Exelixis Inc
is
Undervalued by 14%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.
Let our AI break down the key assumptions behind the intrinsic value calculation for Exelixis Inc.
| FR |
|
Pharnext SCA
OTC:PNEXF
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Exelixis remains heavily reliant on cabozantinib-based therapies for revenue, exposing it to significant downside risk if competition or unfavorable trial data diminishes demand for this cornerstone product.
The company’s pipeline diversification efforts beyond cabozantinib have yet to demonstrate substantial commercial viability, raising concerns about the long-term sustainability of its R&D strategy.
Exelixis faces increasing patent and pricing pressures, as competitors target the same oncology segments with novel therapies, potentially undermining the firm’s margins and market share.
Cabometyx has shown strong clinical performance in multiple indications, and its success in kidney and liver cancers could lead to expanded use cases and sustained revenue growth.
Exelixis has historically maintained strategic partnerships with larger pharmaceutical companies, which helps reduce commercialization costs and expand global reach for its lead products.
A growing cash position and disciplined approach to R&D spending have provided Exelixis with the flexibility to pursue new drug candidates without significantly endangering its balance sheet.
Revenue & Expenses Breakdown
Exelixis Inc
Balance Sheet Decomposition
Exelixis Inc
| Current Assets | 1.4B |
| Cash & Short-Term Investments | 988.5m |
| Receivables | 309.7m |
| Other Current Assets | 104m |
| Non-Current Assets | 1.4B |
| Long-Term Investments | 578.3m |
| PP&E | 104.7m |
| Intangibles | 63.7m |
| Other Non-Current Assets | 674.6m |
| Current Liabilities | 373.8m |
| Accounts Payable | 25.3m |
| Accrued Liabilities | 185.6m |
| Other Current Liabilities | 162.9m |
| Non-Current Liabilities | 289.1m |
| Other Non-Current Liabilities | 289.1m |
Free Cash Flow Analysis
Exelixis Inc
| USD | |
| Free Cash Flow | USD |
Earnings Waterfall
Exelixis Inc
|
Revenue
|
2.3B
USD
|
|
Cost of Revenue
|
-77.2m
USD
|
|
Gross Profit
|
2.2B
USD
|
|
Operating Expenses
|
-1.4B
USD
|
|
Operating Income
|
820.3m
USD
|
|
Other Expenses
|
-142.3m
USD
|
|
Net Income
|
677.9m
USD
|
EXEL Profitability Score
Profitability Due Diligence
Exelixis Inc's profitability score is 69/100. The higher the profitability score, the more profitable the company is.
Score
Exelixis Inc's profitability score is 69/100. The higher the profitability score, the more profitable the company is.
EXEL Solvency Score
Solvency Due Diligence
Exelixis Inc's solvency score is 80/100. The higher the solvency score, the more solvent the company is.
Score
Exelixis Inc's solvency score is 80/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
EXEL Price Targets Summary
Exelixis Inc
According to Wall Street analysts, the average 1-year price target for
EXEL
is 45.9 USD
with a low forecast of 30.3 USD and a high forecast of 63 USD.
Dividends
Current shareholder yield for
EXEL is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
EXEL
stock under the Base Case scenario is
47.98
USD.
Compared to the current market price of 41.28 USD,
Exelixis Inc
is
Undervalued by 14%.